ClinicalTrials.gg
Status unknownNCT04948151RESPONDUpdated Jul 1, 2021

Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

A Phase 2 interventional study of Sildenafil and Placebo in Female Sexual Arousal Disorder, sponsored by Strategic Science & Technologies, LLC. Status unknown at 51 sites in United States. Open to female participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-01.

Sponsored by Strategic Science & Technologies, LLC · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
21 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Sexual Dysfunction, Physiological with a site in United States — 16 open to participants now, 17 under way, none of them phase 3. Sexual Dysfunction, Physiological · United States.

Planned enrollment
10th of 107
440 · median 60
Started
2021
with 2 others
Phase 2
14 of 127
none open now
Registered
100th of 127
by date

Among the 127 studies in Sexual Dysfunction, Physiological with a site in United States, this one is the 10th largest by planned enrollment of the 107 interventional ones that give a count, is one of 3 that started in 2021, is one of 14 in phase 2, and was the 100th registered.

Sexual Dysfunction, Physiological

385 studies on the registry are indexed under Sexual Dysfunction, Physiological; 72 are open to participants now.

Browse Sexual Dysfunction, Physiological studies →

Open to participants now

16 of the 127 studies in Sexual Dysfunction, Physiological with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Sexual Dysfunction, Physiological studies recruiting now, 23 (50%) set no upper age limit and 20 (43%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 21 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Sexual Dysfunction, Physiological with a site in United States, or all of them as a file.
02

Study summary

This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue.

03

Conditions studied

  • Female Sexual Arousal Disorder

Keywords

  • Sexual Disorder
  • Arousal Disorder
  • FSAD
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be a premenopausal woman, 21 years or older.

    a. Transgender individuals assigned a female gender at birth will be permitted to enroll provided they are not currently undergoing hormone treatment, have not undergone gender reassignment surgery and do not intend to for the duration of the study.

  2. Patient is fluent in the English language.
  3. Patient is capable of understanding and complying with the protocol and agrees to sign the document.
  4. Patient has been in a stable, monogamous, relationship that was secure and communicative, for at least 6 months prior to Visit 1. The relationship is with one sexual partner, who is sexually functional, both psychologically and physically. The partner will be consistent and available throughout the duration of the study.
  5. Based on the clinical interview, in their past, patient had experienced 'normal' sexual function for at least 2 years or longer. Patient has had sexual activity at least two times each month during the last 6 months and agrees to have sexual activity at least two times each month for the duration of the study). Sexual activity can include any activity which may result in sexual stimulation or sexual pleasure e.g., intercourse, caressing, foreplay, masturbation, and oral sex.

    a. Patients who have experienced a recent major life stress (e.g., loss of income, death of a family member) or relationship discord that could interfere with sexual activity (except distress related to FSAD) will be excluded.

  6. Women of must agree to continue using an acceptable form of during the study and agree to continue to stay on their dose of birth control throughout the duration of the study. Birth control is not required for confirmed same sex couples, couples with confirmed vasectomy or couples with confirmed tubal ligation.

    1. Acceptable forms of birth control include the following: intrauterine system [IUS], progestin and/or estrogen-containing hormonal oral contraceptives, contraceptive patch, contraceptive implant, contraceptive injection, or the copper-containing intrauterine device (IUD). Patients must be using the progestin and or estrogen-containing hormonal oral contraceptives or contraceptive patch for least 6 months prior to Visit 1 without complications in the opinion of the Investigator. Patients must be using the IUS, IUD, contraceptive implant, or contraceptive injection for at least 3 months prior to Visit 1 without clinically significant complications in the opinion of the Investigator.
    2. Vaginal forms of contraception such as contraceptive foams/gels, diaphragms, penile or vaginal condoms, contraceptive vaginal rings, and are not considered acceptable methods of birth control in this study.
    3. While latex and polyisoprene condoms are not an acceptable form of contraception, they may be used for the prevention of sexually transmitted infections.
  7. Patient has a (BMI) from 18 to 35 kg/m2, inclusive.
  8. Patient has had a Pap smear performed within three years prior to Visit 1 and can provide documentation indicating normal test results (based on current guidelines as published by the U.S. Preventive Services Task Force).

    a. If the patient cannot provide documentation, a Pap smear will be performed at Visit 1.

    Patients with abnormal findings will be excluded from study participation and be referred for follow-up medical care as appropriate.

  9. Patient is medically healthy with no clinically significant medical history, physical examination, gynecological history and examination, laboratory profiles (e.g., hematology, urinalysis), vital signs (e.g., uncontrolled hypertension), or ECGs, as deemed by the Investigator.

    1. Patients who have clinically significant abnormalities at Visit 1 as confirmed by the Investigator will be excluded.
    2. Patients with controlled, treated hypertension (\<140/90 mmHg) on up to two medications (excluding alpha blockers and nitrates) with a stable dose for the past 6 months will be considered eligible.
    3. Patients with controlled, treated thyroid disease on a stable medication and dose for the past 6 months will be considered eligible. TSH must be within normal range (confirmed by laboratory test).
  10. The participant must agree to not use vaginal hormone therapy (e.g., vaginal estrogen, intravaginal prasterone), vaginal or vulvar lubricants, spermicides, creams or gels, contraceptive foams or vaginal douche products throughout the study period.

    1. Women who self-report abnormal physiological vaginal discharge will be excluded until abnormal physiological discharge resolves.
    2. Patients using systemic (transdermal or oral) therapy must be on a stable dose for at least 6 months prior to Visit 1.
  11. Patient must have a total score on the FSDS-DAO >18 through visit 4.

Exclusion criteria

Exclusion Criteria - For Patient Eligibility

  1. Patient is nursing or pregnant (based on positive serum pregnancy test), wishes to become pregnant or begin nursing during the study period or was pregnant or nursing within 6 months prior to Visit 1.
  2. Patient has more than one sexual partner.
  3. Patient is (surgically induced or natural) meeting any of the following criteria:

    1. Bilateral oophorectomy.
    2. 12 months of spontaneous amenorrhea
    3. 6 months of spontaneous amenorrhea with serum FSH levels >40mIU/mL (except for those women on hormone replacement therapy)
  4. Patient has any disorder or a history of any disorder that may prevent the successful completion of the study in the opinion of the Investigator.
  5. Patient has a significant cardiovascular, hepatic, metabolic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, genitourinary, or other unstable medical condition that would contraindicate administration of study medication, interfere with study evaluation, limit study participation, or confound the interpretation of study results in the opinion of the Investigator.
  6. Patient has a history of unresolved sexual trauma or abuse that is contributing to any sexual dysfunction problem (desire, arousal, orgasm, etc.) as determined by the clinical interview.
  7. Patient with any history of active peptic ulcers or bleeding disorders.
  8. Patient with a history of clitoral priapism or conditions which may predispose them to clitoral priapism (such as sickle cell anemia, multiple myeloma, or leukemia).
  9. Patients with a history of myocardial infarction, stroke, or life-threatening arrhythmia within 6 months prior to Visit 1; patients with resting hypotension (BP \<90/50 mmHg); or any history of coronary disease causing angina; or congestive heart failure requiring medical intervention; patients with underlying conditions which can be particularly sensitive to the actions of vasodilators including patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and patients with impaired autonomic control of blood pressure, or for those for which sexual activity is inadvisable due to their underlying cardiovascular status.
  10. Patient with a history of hearing loss (unless born completely deaf).
  11. Patient has retinitis pigmentosa, even if the patient feels clinically well at the time of Visit 1. Patients with retinitis pigmentosa will be identified by specifically asking whether they have the condition, if there are visual signs and symptoms of the condition (including questioning patients as to whether they have difficulty seeing at night or in low light, and if they have any visual field deficits that indicate a loss of peripheral or central vision), or if there is a family history.
  12. Patient has a history of orthostatic hypotension or orthostatic hypotension which is present at Visit 1, defined as a drop in systolic blood pressure ≥ 20 mm Hg, a drop in diastolic blood pressure ≥ 10 mm Hg, an increase in pulse by 20 beats per minute or experiencing lightheadedness or dizziness at 1 or 3 minutes after the change in position from supine to standing.
  13. Patient has a primary complaint of anorgasmia, vaginismus, low desire, or any other primary sexual complaint aside from problems with genital arousal, as determined by the clinical interview.
  14. Patient has untreated dyspareunia, vulvovaginal infection or inflammation, inflammatory disorders of the vulva or vagina, vestibulodynia, clitorodynia, or symptomatic vulvovaginal atrophy (defined as women having ≤5% of superficial cells on vaginal smear at baseline,
  15. Patient has undergone major pelvic or abdominal surgery that may have caused nerve damage, including, vulvectomy, colostomy, cystostomy, hysterectomy and bladder neck suspension.
  16. Patients with comorbid conditions that may cause underlying neurological impairment (i.e., Type 1 or Type 2 diabetes, metabolic syndrome, stroke, myasthenia gravis, multiple sclerosis or spinal cord damage) will be excluded.

    a. Patients who are symptomatic of peripheral neuropathy will be excluded.

  17. Patients with pelvic nerve damage secondary to trauma will be excluded.
  18. With the exception of anxiety and depression, patient has any current and/or previously reported diagnoses of axis I disorders (e.g., schizophrenia, bipolar disorder) including delirium, dementia and amnestic disorders.

    1. Patients diagnosed with anxiety or depression must be controlled, as determined by the Investigator, and if on a medication (i.e., SSRIs, SNRIs, buspirone, bupropion, and benzodiazepines), on a stable dose for at least the past 6 months.
    2. Patients must have a total score \<10 indicating mild depression on the Patient Health Questionnaire-8 (PHQ-8, Appendix G) (a screening and assessment instrument for depression).
    3. Patients must have a total score \<6 indicating mild anxiety on the Generalized Anxiety Disorder (GAD-7, Appendix H) (a screening and assessment instrument for anxiety).
    4. Patients who have any history of anti-psychotic therapy within the last year will be excluded.
  19. Patients that have a history of gynecological cancer or are under active treatment (or recently completed treatment within the last 6 months) for any cancer which in the Investigator's judgement would interfere with the patient's ability to successfully complete the study will be excluded.

    1. Patients who have been previously treated for dysplasia (precancerous changes) may be included as long as the patient received localized treatment (e.g., cryosurgery or laser).
    2. Patients with a history of radiation to the pelvis will be excluded.
  20. Patient has any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the test article in the opinion of the Investigator.
  21. Patient self-reports a history of substance abuse within two years prior to Visit 1 or exhibits signs of current substance abuse based on Investigator judgement.
  22. Patient self-reports a history of alcohol abuse in the two years prior to Visit 1 or exhibits signs of current alcohol abuse based on Investigator judgement.
  23. Patient has a history of non-arteritic ischemic optic neuropathy (NAION) or any underlying NAION risk factors.
  24. Patient whose sexual function was affected (enhanced or worsened) by any medication within 28 days before Visit 1 and at any time prior to the No Drug Run-in Period of the study.
  25. Patient is currently receiving treatment or has received treatment within 1 month (28 days) prior to Visit 1 of any of the following medications: guanylate cyclase stimulators (e.g., Riociguat), clonidine, strong inhibitors, nitric oxide donors, such as organic nitrates or organic nitrites, and alpha blockers.

    a. Patients who are currently receiving treatment or have received treatment in the past 3 months for FSAD symptoms, pharmacologic (e.g., PDE5 inhibitors in any form except Sildenafil Cream, 3.6% or other experimental therapies used to enhance the arousal response) or non-pharmacologic treatment (e.g., sex therapy), will also be excluded.

  26. Patient has positive findings from the urine drug screen (e.g., amphetamines, barbiturates, cocaine, methadone, and opiates). Patients who test positive for amphetamines but are being treated for ADHD with a confirmed legal prescription will be allowed to participate.
  27. Patient has positive findings for sexually transmitted infection (gonorrhea, trichomoniasis, chlamydia), and (HIV) antibodies.
  28. Patient reports having an outbreak (blisters, warts, or vesicles) due to any of the following sexually transmitted diseases: genital herpes or HPV at any time point in the past three months.
  29. Patient has participated in any clinical research study evaluating another drug or therapy within 30 days before Visit 1 (or 6 half-lives of the investigational agent, whichever is longer) and agrees not to participate in another clinical research study throughout the duration of the study.
  30. Patient has any clinically significant abnormal findings on vulvar-vaginal examination performed during the physical and gynecological exams at Visit 1 (e.g., genital skin breaks, irritation, dermatoses, or lesions).
  31. Patient currently has moderate to severe current vaginitis, a vaginal infection including bacterial vaginosis, a yeast infection or the presence of yeast based on the Nucleic Acid Amplification (NAAT).

    1. If the patient has a vaginal infection or a positive test for yeast during the screening visit, they may be treated, and the screening visit rescheduled.
    2. If the patient develops a vaginal infection following enrollment into the study, study drug will be withheld, and the patient will be treated for the infection. If the infection cannot be resolved within two weeks the patient will be withdrawn from the study. Treatment of vaginal infections will be allowed twice following enrollment. If the patient develops a third vaginal infection they will be withdrawn from the study.
  32. Patient has a pelvic or urinary tract infection.

    1. If the patient has a urinary tract infection during the screening visit, they may be treated, and the screening visit rescheduled.
    2. If the patient develops a urinary tract infection following enrollment into the study, study drug will be withheld, and the patient will be treated for the infection. If the infection cannot be resolved within two weeks the patient will be withdrawn from the study. Treatment of urinary tract infections will be allowed twice following enrollment. If the patient develops a third urinary tract infection they will be withdrawn from the study.
  33. Patient self-reports a known or adverse reaction to any ingredients in the Investigational Product (IP).
  34. The patient is an immediate family member, a study site employee, or is in a dependent relationship with a study site employee or anyone who is involved in the conduct of the study (e.g., spouse, parent, child, sibling) or may consent under duress.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
440 participants (estimated)

Study arms

  • Experimental
    Sildenafil Cream, 3.6%

    Drug: Sildenafil

  • Placebo comparator
    Placebo Cream

    Drug: Placebo

Interventions

  • Patients will apply 2-gram applications up to 9 times per month.

  • DrugPlacebo

    Patients will apply 2-gram applications up to 9 times per month

06

What researchers measure

Primary outcomes

  1. SFQ28 (AS) - 28 Day Recall

    Evaluating the efficacy of Sildenafil Cream, 3.6% measured by change from baseline to end of study in the Arousal-Sensation Domain of the SFQ28.

    Time frame: SFQ28 score at the end of the Single-Blind Placebo Run-In to the end of the 12-Week Double-blind Dosing period.

  2. FSDS-DAO (Q14) - 28 Day Recall

    Evaluating the efficacy of Sildenafil Cream, 3.6% measured by change from baseline to end of study in the score for feeling concerned by difficulties with sexual arousal - Item #14 only of the FSDS-DAO.

    Time frame: Q14 score at the end of the Single-Blind Placebo Run-In to the end of the 12-Week Double-blind Dosing period.

Secondary outcomes

  1. Arousal Diary (SSE)

    Evaluating the efficacy of Sildenafil Cream, 3.6% measured by change from baseline to end of study in the number of Satisfactory Sexual Events, question #11 in teh ARousal Diary.

    Time frame: measured by daily prompt within 24hrs after each sexual event during the Single-Blind Placebo Run-In compared to the last 4 weeks of the Double-Blind Dosing Period.

07

Study locations

51 of 51 sites recruiting
  • Coastal Clinical Research
    Mobile, Alabama 36608, United States
    Recruiting
  • Precision Clinical Trials-Arizona
    Phoenix, Arizona 85032, United States
    Recruiting
  • Visions Clinical Research -Tucson
    Tucson, Arizona 85712, United States
    Recruiting
  • Collaborative Neuroscience Network
    Garden Grove, California 92845, United States
    Recruiting
  • NRC Research Institute
    Orange, California 92868, United States
    Recruiting
  • Medical Center for Clinical Research - San Diego
    San Diego, California 92108, United States
    Recruiting
  • Schuster Medical Research Institute
    Sherman Oaks, California 91403, United States
    Recruiting
  • Downtown Women's Healthcare
    Denver, Colorado 80209, United States
    Recruiting
  • Coastal Connecticut Research, LLC
    New London, Connecticut 06320, United States
    Recruiting
  • Intimmedicine Specialists
    Washington, District of Columbia 20036, United States
    Recruiting
  • South Florida Medical Research
    Aventura, Florida 33180, United States
    Recruiting
  • AMR Fort Myers
    Fort Myers, Florida 33912, United States
    Recruiting
  • Clinical Neuroscience Solutions-Orlando
    Jacksonville, Florida 32256, United States
    Recruiting
  • New Age Medical Research Corporation
    Miami, Florida 33186, United States
    Recruiting
  • Suncoast Clinical Research - Pasco County
    New Port Richey, Florida 34652, United States
    Recruiting
  • Healthcare Clinical Data, Inc.
    North Miami, Florida 33161, United States
    Recruiting
  • CNS Healthcare
    Orlando, Florida 32801, United States
    Recruiting
  • Comprehensive Clinical Research, LLC
    West Palm Beach, Florida 33409, United States
    Recruiting
  • AGILE Clinical Research Trials
    Atlanta, Georgia 30342, United States
    Recruiting
  • iResearch Atlanta
    Decatur, Georgia 30030, United States
    Recruiting
  • Rosemark Women Care Specialists
    Idaho Falls, Idaho 83404, United States
    Recruiting
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
    Recruiting
  • Cypress Medical Research Center
    Wichita, Kansas 67226, United States
    Recruiting
  • Southern Institute for Women's Sexual Health
    Covington, Louisiana 70433, United States
    Recruiting
  • Praetorian Pharmaceutical Research
    Marrero, Louisiana 70072, United States
    Recruiting
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
    Recruiting
  • Women's OB-GYN, P.C. dba Saginaw Valley Medical
    Saginaw, Michigan 48604, United States
    Recruiting
  • Quality Clinical Research
    Omaha, Nebraska 68114, United States
    Recruiting
  • Omaha OB GYN Associates, P.C.
    Omaha, Nebraska 68130, United States
    Recruiting
  • Essential Women's Health Associates
    Las Vegas, Nevada 89113, United States
    Recruiting
  • Office of Doctor Rex G. Mabey Junior
    Las Vegas, Nevada 89128, United States
    Recruiting
  • Women's Health Research Center
    Lawrenceville, New Jersey 086489, United States
    Recruiting
  • New Jersey Urology - Bloomfield
    Millburn, New Jersey 07041, United States
    Recruiting
  • The Center for Specialized Women's Health
    Morristown, New Jersey 07960, United States
    Recruiting
  • Suffolk Obstetrics and Gynecology
    Port Jefferson, New York 11777, United States
    Recruiting
  • Velocity Clinical Research - Cleveland (Rapid Medical Research)
    Cleveland, Ohio 44122, United States
    Recruiting
  • Aventiv Research, inc.
    Columbus, Ohio 43214, United States
    Recruiting
  • University Hospitals Landerbrook
    Mayfield Heights, Ohio 44124, United States
    Recruiting
  • Rivus Wellness & Research Institute
    Oklahoma City, Oklahoma 73112, United States
    Recruiting
  • Velocity Clinical Research, Providence
    Warwick, Rhode Island 02886, United States
    Recruiting
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
    Recruiting
  • ClinSearch
    Chattanooga, Tennessee 37421, United States
    Recruiting
  • Clinical Neuroscience Solutions - Memphis
    Memphis, Tennessee 38119, United States
    Recruiting
  • Medical Research Center of Memphis
    Memphis, Tennessee 38120, United States
    Recruiting
  • Urology Associates - Nashville
    Nashville, Tennessee 37209, United States
    Recruiting
  • TMC Life Research
    Houston, Texas 77054, United States
    Recruiting
  • Maximos Obstetrics and Gynecology
    League City, Texas 77573, United States
    Recruiting
  • Clinical Trials of Texas
    San Antonio, Texas 78229, United States
    Recruiting
  • Health Research of Hampton Roads, Inc.
    Newport News, Virginia 23606, United States
    Recruiting
  • Tidewater Clinical Research
    Norfolk, Virginia 23502, United States
    Recruiting
  • Seattle Women's Health Research - Gynecology
    Seattle, Washington 98105, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2021; primary completion for Dec 2021, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2021
First posted
Jul 1, 2021
StartEst.
Jun 28, 2021
Primary completionEst.
Dec 15, 2021
CompletionEst.
Dec 15, 2021
Last update
Jul 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04948151
Lead sponsor
Strategic Science & Technologies, LLC
Collaborators
Daré Bioscience, Inc.
Responsible party
Sponsor
First posted
Jul 1, 2021
Start date
Jun 28, 2021 (estimated)
Primary completion
Dec 15, 2021 (estimated)
Completion
Dec 15, 2021 (estimated)
Last update
Jul 1, 2021

Study contacts

Kathy Cornell
Contact
kcornell@strategicscience.com
774-473-4414

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion